Skip to content
JCP
PCC
News
CME
About
Authors
Sign In
Subscribe
Search
Advanced Search
Menu
JCP
PCC
News
CME
About
Authors
Sign In
Subscribe
Clinical Topics
View All
Depression
Neurologic
Anxiety
Schizophrenia
Trauma
Psychopharmacology
Bipolar
Tardive Dyskinesia
OCD
Addiction
View All
Columns
View All
ASCP Corner
Clinical & Practical Psychopharmacology
Rounds General Hospital
Academic Highlights
Banner Alzheimer’s Institute
Focus on Geriatric Psychiatry
Paul Andreason, MD
JCP
Review Article
FDA Perspective on Pimavanserin
June 28, 2017
In 2016, pimavanserin became the only FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis. This article describes the regulatory and clinical issues important to the FDA's...
Mitchell V. Mathis
,
Brendan M. Muoio
,
Paul Andreason
, et al